Connect with us

Technology

Ovation.io and PD Theranostics (PDTx) Complete Merger Creating a Multiomic Data Company Which Owns a Unique Population-Scale Biobank of Disease-Specific Biospecimens

Published

2 years ago

on

Ovation owns a unique population-scale biobank of consented and linkable disease-specific biospecimens, which includes more than 1.6 million samples from over 600,000 United States-based patients; approximately one-third are tissue samples. Ovation plans to continue expanding the biobank with the addition of 200,000 + patient samples per monthOvation’s biobank includes tissue, blood, and other sample types from patients with diseases of current discovery and development interest including inflammatory bowel disease (IBD), liver disease, chronic kidney disease (CKD), cardio-metabolic/GLP-1, various types of cancers, and neurodegenerative diseases such as Alzheimer’s diseaseThe Company plans to produce a database of linked omics and patient/clinical data for each diseaseThe merger combines teams with deep domain expertise in human genetics, disease pathogenesis, and pathology

PORTLAND, Maine and BOSTON, Sept. 5, 2024 /PRNewswire/ — Ovation.io and PDTx today announced the completion of their merger. The new entity creates an industry-leading multiomics data company managed by a team with deep expertise in genomics data, sequencing, bioinformatics, cell biology, and imaging, AI/ML and data commercialization. The Company’s enhanced platform capabilities and data libraries can drive deeper insights into cellular biology and gene expression for research, drug development, and clinical decision-making, and across a broad range of diseases.

“We believe the two companies are deeply complementary and will provide our customers with best-in-class, diverse multiomics data,” said Curt Medeiros, CEO of Ovation. “These one-of-a-kind data sets will combine Ovation’s DNA and RNA sequencing of patient samples in a given disease state with PDTx’s mapping of cellular footprints, spatial context, immune system functionality and markers, as well as clinical pathology imaging. This will help drive our client’s R&D efforts, from target and biomarker discovery, through optimized clinical trial enrollment.”

Human genomic data has become an increasingly important tool in disease target and biomarker discovery. By analyzing an individual’s genetic makeup, especially in relation to clinical progression and outcomes, researchers are able to better understand the underlying causes of diseases and identify potential therapeutic targets and biomarkers. Ovation is building the world’s broadest commercially available human genomic dataset that brings together whole genome sequences with longitudinal clinical records at the patient level (“clinic-genomics data”) to address the speed and cost at which new research efforts can be powered by human genomics. This clinic-genomics database will enable a depth and breadth of analytics not currently possible due to the scale, continuous flow of new patient samples, and diversity of patients.

“The Ovation and PDTx teams are energized and have been collaborating for the past year to position our first proof-of-concept programs in IBD and prostate cancer for groundbreaking results,” said Patrick Gallagher, CEO of PDTx. “The in-house biobank will allow the team to accelerate data generation and more fully leverage the PDTx platform’s high dimensional, multiomic modalities that characterize cellular status. This includes changes in and predictiveness of proteins, glycans, metabolites and cell-cell spatial relationships that can drive discovery and correlations with pathological features of disease severity, progression and therapeutic response.”

PDTx has developed a disease-agnostic platform to analyze data collected across multiple high-dimensional imaging technologies to discover new drug development targets and identify critical biomarkers of disease progression and therapeutic response. The PDTx platform provides the ability to visualize the presence, concentration, and distribution of molecules and analyze intra- and inter-molecular and phenotypic single-cell relationships and their impact on morphology. Ovation will retain PDTx’s exclusive global license for the platform and its intellectual property from Massachusetts General Hospital (MGH) and the Vaccine and Immunotherapy Center (VIC) at (MGH).

“Ovation’s ability to continuously scale its biobank and data to expand its curated disease cohorts that are representative of racial and geographic diversity in the United States is completely novel,” noted Mike Self, co-founder of StageDotO Ventures. “Linking this with longitudinal patient data creates a totally unique product that will allow for more targeted and efficient investment in development programs for our clients.”

By combining imaging and sequencing, state-of-the-art multiomics can map the location of specific proteins and chemical products in tissues and identify the location of presence of these chemical entities. This provides a critical perspective about the cellular microenvironment and inter-cellular interactions in biopsies of diseased tissue.

“We are incredibly excited to collaborate with the research team at Ovation,” said Mark Poznansky, M.D., Ph.D, director of the Vaccine and Immunotherapy Center at Massachusetts General Hospital. ” Connecting genetic data with cellular, structural and chemical details of tissue affected by IBD or prostate cancer can lead to important translational medical progress. For example, our combining a multiomics platform that provides information on both the genetic and protein signature in blood as well the location of specific chemicals and cells within a tissue, can help identify new sets of biomarkers that are potentially impactful diagnostically and prognostically as well as revealing of new disease related therapeutic targets.”  

About Ovation
Ovation is an omics data company committed to accelerating the development of precision medicine. Ovation provides life sciences R&D teams access to high-quality omics data linked to rich, longitudinal clinical data, across therapeutic areas, at population scale. Ovation’s data increases the probability of success for drug discovery by enabling the identification and validation of biomarkers and therapeutic targets. The company has an extensive biobank of more than 1.6 million geographically diverse, consented biospecimens from over 625,000 unique patients. For more information, visit www.ovation.io or follow the company on LinkedIn.

About PD Theranostics
PDTx is a data driven healthcare company focused on leveraging proprietary workflows and using multi parameter imaging-based methodologies to generate robust, one-of-a-kind multi-omic cellular biology based databases for numerous disease states. Our proprietary imaging processes, driven by a multi-omics approach, will generate spatial roadmaps of human cancers and other diseases, leading to unparalleled data richness and depth. Through our ability to map tissue structures and immune populations, we believe we could more clearly define disease stage, and likelihood of disease progression, and identify the most efficacious treatment regimens for each patient.

Contact Information
Info@ovation.io

Forward-Looking Statement
This press release includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include, but are not limited to, statements that relate to the advancement and development of the Ovation Platform and other information that is not historical information. When used herein, words such as “anticipate”, “being”, “will”, “plan”, “may”, “continue”, and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance, or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based on Ovation’s current expectations and various assumptions. Ovation believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. Ovation may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various important factors, including, without limitation, market conditions. Consequently, forward-looking statements should be regarded solely as Ovation’s current plans, estimates and beliefs. Investors should not place undue reliance on forward-looking statements. Ovation cannot guarantee future results, events, levels of activity, performance or achievements. Ovation does not undertake and specifically declines any obligation to update, republish, or revise any forward-looking statements to reflect new information, future events or circumstances or to reflect the occurrences of unanticipated events, except as may be required by law.

View original content to download multimedia:https://www.prnewswire.com/news-releases/ovationio-and-pd-theranostics-pdtx-complete-merger-creating-a-multiomic-data-company-which-owns-a-unique-population-scale-biobank-of-disease-specific-biospecimens-302239632.html

SOURCE Ovation.io

Related Topics:
Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

Market Defense Expands Capabilities with Acquisition of Knoza by Parent Company D2E Labs

Published

5 minutes ago

on

April 30, 2026

By

SEATTLE, April 29, 2026 /PRNewswire/ — Market Defense today announced its expansion through the acquisition of Knoza by its parent company, D2E Labs. This strategic move reinforces Market Defense’s ambition to deliver seamlessly connected marketplace operations and high-impact, full-funnel marketing solutions to brands at every stage of their growth journey.

The addition of Knoza brings a highly complementary service model to Market Defense, combining strong marketplace expertise with on- and off-Amazon performance marketing capabilities. Knoza has built a reputation for supporting emerging brands with agile, performance-driven strategies tailored to early-stage growth, making it a natural fit within the broader Market Defense ecosystem.

Through this integration, Market Defense strengthens its ability to provide clients with a unified and scalable approach to commerce and marketing, bridging channels and optimizing performance across the entire customer journey.

Enhanced Client Capabilities

Clients of Market Defense will benefit from:

Full-funnel customer acquisition through off-Amazon performance marketing strategy and execution across Meta and GoogleA seamlessly connected digital commerce platform spanning Amazon, TikTok, Target, Ulta, and WalmartAdvanced AI-powered tools and actionable insightsOptimized service models aligned with each client’s maturity, needs, and growth stage

“This acquisition reflects our clear ambition to connect every aspect of our clients’ marketplace operations while delivering truly integrated, high-impact marketing solutions,” said Karan Raturi, Chief Operating Officer at Market Defense. “Knoza brings a complementary approach and deep expertise that strengthens our ability to support brands from early-stage growth through to global scale.”

Raturi added, “By combining Knoza’s agility and performance-driven mindset with Market Defense’s technology, platform reach, and strategic depth, we are creating a more powerful, end-to-end solution for our clients. This is ultimately about helping brands grow faster, more efficiently, and across more channels.”

The integration of Knoza marks another important step in Market Defense’s ongoing expansion and commitment to delivering best-in-class marketplace and marketing solutions.

About Market Defense
Market Defense is the leading marketplace and digital marketing services specialist, delivering seamlessly connected marketplace operations and full funnel growth strategies.

About Knoza
Knoza is a performance-driven marketplace agency specializing in on- and off-Amazon growth strategies for emerging brands.

About D2E Labs
D2E Labs is a commerce-focused group building and scaling best-in-class companies that power growth for brands across digital ecosystems.

Media Contact:
Vanessa Kuykendall
Chief Engagement Officer
vanessa@marketdefense.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/market-defense-expands-capabilities-with-acquisition-of-knoza-by-parent-company-d2e-labs-302758067.html

SOURCE Market Defense LLC

Continue Reading

Technology

Dreame Technology’s “DREAME NEXT” Smart Wearables: Smart Ring Comes Under the Spotlight

Published

5 minutes ago

on

April 30, 2026

By

SAN FRANCISCO, April 29, 2026 /PRNewswire/ — Dreame Technology, a global leader in smart home appliances and health technology, today held its “DREAME NEXT” themed launch event at the Palace of Fine Arts in San Francisco.

Dreame stated that this launch event aims to redefine the next generation of lifestyle, serving as the prologue to the next decade of Dreame Technology’s long-term development from a global perspective.

Among the new products, the Dreame Ring series stood out as one of the highlights of the event.

In terms of product design, the Dreame Ring achieves a breakthrough in wearing experience. It features an aviation-grade titanium alloy outer ring and a hypoallergenic epoxy resin inner ring, ensuring durability and texture while greatly enhancing skin-friendly comfort. With a thickness of just 2.5 millimeters and a weight as low as 2.6 grams, the ring delivers an almost “unnoticeable” wearing experience.

This design effectively solves the common problem of traditional smart wearables being abandoned due to discomfort, allowing users to wear the ring all day – including while sleeping – so that health observation and smart reminders become seamlessly integrated into daily life.

Three Product Lines: Deep Integration of Function and Aesthetics

The Dreame Ring series announced today includes three core products:

The first product is the Dreame AI Smart Ring. It features an ultra-compact world-leading vibration motor, pioneering refined fingertip haptic feedback technology, and integrates multiple sensors within an industry-leading ultra-thin design of just 2.5 millimeters. It provides vibrating alerts for various reminders, such as prolonged sitting, hydration, medication, and other notifications.

The second is the Dreame AI NFC Smart Ring, which serves as an “ecosystem key” by integrating access cards, keys, and digital passes for seamless connectivity.

The third is the Dreame Glow Ring, which continuously monitors heart rate, blood oxygen, body temperature, respiratory rate, and sleep structure around the clock, providing efficient sleep analysis, activity tracking, and health risk assessment.

High-Luxury Jewelry System: From Everyday Wear to Heirloom Collection

In terms of product positioning, Dreame plans to introduce high-luxury jewelry materials into its ring lineup, featuring 18K gold (yellow, white, and rose gold) and Pt950 platinum, paired with natural diamonds and precious gemstones such as sapphires, rubies, and emeralds, with support for personalized customization. The craftsmanship includes hollow carving, compound stone setting, and traditional hand-engraving techniques, with each piece finished by hand-polishing.

Dreame stated that the future direction of wearable devices is not to emphasize the presence of technology, but to allow technology to serve users invisibly. The AI high-luxury smart ring is the embodiment of this trend – it is no longer a device that needs to be “used,” but an intelligent presence that accompanies users over the long term.

About Dreame Technology
Established in 2017, Dreame Technology is a global leader in high-end consumer electronics and intelligent manufacturing with the vision to empower lives through technology. Follow us on Facebook, Instagram, TikTok and Twitter. For more information, please visit https://www.dreametech.com/.

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/dreame-technologys-dreame-next-smart-wearables-smart-ring-comes-under-the-spotlight-302757184.html

SOURCE Dreame Technology

Continue Reading

Technology

EA Automatic Announces Next Generation Intelligent Trading Solutions Built for Performance, Precision, and Long-Term Growth

Published

1 hour ago

on

April 29, 2026

By

Redefining algorithmic trading through personalized strategies, AI-enhanced systems, and expert human oversight

LONDON, April 29, 2026 /PRNewswire/ — In today’s fast-moving financial landscape, where market conditions shift in seconds and opportunities are often measured in milliseconds, traders and investors are increasingly turning to technology to stay competitive. EA Automatic has officially announced the launch and expansion of its intelligent automated trading solutions, designed to deliver precision, adaptability, and performance without sacrificing strategic control.

Positioned at the intersection of advanced technology and real-world trading expertise, EA Automatic is setting a new standard in algorithmic trading. The company offers more than just trading bots. It delivers fully integrated trading systems built around the individual goals, risk tolerance, and long-term ambitions of each client.

At its core, EA Automatic is driven by a simple but powerful philosophy. Automation alone is not enough. True success in trading comes from combining intelligent systems with informed human decision-making. This belief has shaped every aspect of the company’s platform, resulting in solutions that go beyond execution to deliver meaningful, consistent performance.

A Personalized Approach to Automated Trading

One of the defining features of EA Automatic is its commitment to customization. In an industry where many platforms rely on rigid, one-size-fits-all models, EA Automatic takes a fundamentally different approach.

Every investor is unique. Financial goals, risk appetite, and investment timelines vary widely from one individual to another. Recognizing this, EA Automatic designs and deploys trading strategies that are tailored specifically to each client’s profile.

Whether the objective is steady monthly income, capital preservation, or aggressive growth through higher risk strategies, the platform adapts accordingly. By aligning each system with clearly defined goals, EA Automatic ensures that clients are not simply participating in the market but doing so with purpose and direction.

This level of personalization is further enhanced through smart diversification. Rather than relying on a single strategy or market condition, EA Automatic spreads risk intelligently across multiple approaches. This creates a more stable trading environment and helps protect capital even during periods of volatility.

Advanced Technology Built on Real Trading Insight

The EA Automatic platform is the result of more than two and a half years of focused development. During this time, the company has worked to integrate cutting-edge artificial intelligence with practical trading knowledge gained from real market experience.

The result is a system that does not rely solely on algorithms but uses AI to enhance decision-making. Automation handles the speed and efficiency required for modern trading, executing trades with precision and consistency. At the same time, human expertise remains a critical component of the process.

A dedicated team of professional traders continuously monitors performance, evaluates market conditions, and adjusts strategies as needed. This dynamic approach allows the platform to respond to changes in real time while maintaining a structured and disciplined trading framework.

By combining machine efficiency with human oversight, EA Automatic delivers a balanced solution that minimizes emotional decision-making while retaining the flexibility needed to adapt in unpredictable markets.

A Strong Focus on Risk Management and Stability

In an environment where many trading services focus on rapid gains and unrealistic promises, EA Automatic takes a more disciplined and transparent approach. The company places risk management at the center of its strategy development process.

Rather than promising overnight success, EA Automatic emphasizes consistency, structure, and long-term sustainability. Every system is built on proven methodologies designed to reduce unnecessary exposure and protect client capital.

Key risk management principles are embedded into each strategy, including controlled position sizing, diversified asset allocation, and continuous performance monitoring. These elements work together to create a trading experience that prioritizes stability without sacrificing growth potential.

By removing emotional bias and guesswork from the equation, EA Automatic enables clients to engage with the market in a more rational and controlled manner. This structured approach is particularly valuable in volatile conditions, where impulsive decisions can lead to significant losses.

Ongoing Support and a Clear Path to Growth

EA Automatic understands that successful trading is not just about technology. It is also about support, guidance, and transparency. Clients are not left to navigate the platform on their own. Instead, they gain access to a complete trading ecosystem designed to support long-term success.

From initial onboarding to ongoing strategy adjustments, the EA Automatic team works closely with clients to ensure that their systems remain aligned with their evolving goals. This continuous support helps build confidence and allows investors to focus on growth rather than day-to-day market fluctuations.

The company’s commitment to clarity and communication further strengthens this relationship. Clients receive insights into how their strategies operate, what factors influence performance, and how adjustments are made in response to changing conditions.

This level of engagement transforms the trading experience from a passive process into a guided journey, where clients are empowered with both tools and understanding.

Redefining What Automated Trading Means

As automation becomes increasingly common in the financial world, the distinction between basic tools and intelligent systems is becoming more important. EA Automatic is leading this shift by redefining what automated trading can and should be.

Instead of offering standalone bots, the company delivers comprehensive solutions that integrate strategy, technology, and expertise. This approach ensures that clients are not simply executing trades but participating in a structured and well-managed investment process.

By focusing on personalization, advanced technology, and disciplined risk management, EA Automatic is creating a model that is both scalable and sustainable. It is a model designed not for short term speculation but for long term financial growth.

About EA Automatic

EA Automatic is a London-based financial technology company specializing in intelligent automated trading solutions. With a focus on combining artificial intelligence with real trader expertise, the company develops customized algorithmic strategies tailored to individual investment goals and risk profiles.

Built over more than two and a half years of development, the EA Automatic platform emphasizes precision, adaptability, and risk management. Clients benefit from continuous monitoring, expert oversight, and a structured approach designed to deliver consistent results over time.

EA Automatic is committed to helping investors navigate the complexities of modern financial markets with confidence, clarity, and control.

Contact:
EA Automatic
Website https://ea-automatic.com
Email support@ea-automatic.com

Watch the video: Clinton & David Interview [EA Automatic Review]

Photo – https://mma.prnewswire.com/media/2969575/EA_Automatic.jpg

View original content to download multimedia:https://www.prnewswire.com/news-releases/ea-automatic-announces-next-generation-intelligent-trading-solutions-built-for-performance-precision-and-long-term-growth-302758028.html

SOURCE EA Automatic

Continue Reading

Trending